Available IPD datapackage for study 'Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy'

This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab & Pemetrexed or Pemetrexed alone; Cetuximab & Docetaxel or Docetaxel alone).

本试验为一项多中心、开放标签、随机III期临床试验，纳入初始铂类化疗失败后的复发或进展性非小细胞肺癌（Non-Small Cell Lung Cancer, NSCLC）患者。受试者将接受研究者选定的多西他赛（Docetaxel）或培美曲塞（Pemetrexed）化疗方案。在每个化疗分组中，受试者将被随机分配至西妥昔单抗联合化疗组或单纯化疗组，具体分组为：西妥昔单抗联合培美曲塞对比单纯培美曲塞，以及西妥昔单抗联合多西他赛对比单纯多西他赛。